Fig. 1

DHJSD enhances the viability of IL-1β-exposed NP cells (NPCs). a NPCs treated with or without IL-1β and various DHJSD concentrations for 24 h. b NPCs treated with or without IL-1β and 300 µg/mL DHJSD for different phases. NPCs were untreated, treated with IL-1β (10 ng/mL) alone, or with IL-1β (10 ng/mL) and DHJSD (300 µg/mL). c Representative fluorescence images with EDU staining and quantitative analyses of EDU-positive cells (scale bar: 50 μm, original magnification ×200) d The protein content of collagen II, aggrecan, MMP3 and adamts5 of NPCs treated above. All experiments were performed three times in duplicate, and data are shown as average ± SD (n = 3). *P < 0.05 compared with the control, #P < 0.05 in comparison to the IL-1β group